The liver is a major site of metabolism of various drugs. In patients with liver disease the liver capacity for metabolism/ elimination of drugs may be disturbed.(1) Cirrhosis of the liver (hepatic cirrhosis) is one of the severe liver diseases that is chronic, irreversible, and causes high mortality (2) , and this occupies the twelfth leading cause of death in the United States (3) .
Hepatic cirrhosis is a diffuse process characterized by fibrosis and changes of the normal liver structure to abnormal nodule structure.(4) As a result, scar tissue is formed due to injury or long-term liver disease, and it causes the liver to fail its normal functions such as protein synthesis, cleaning process of the blood, resistance to infection, digesting foods, and energy storage. (5) The degree of severity of the liver disease can be divided into three categories with ChildTurcotte-Pugh (CTP) Score. CTP Classification is a system used to classify the degree of liver damage or development of liver disease in hepatic cirrhosis patients. (6, 7) There are some complications of cirrhosis such as ascites, hepatic encephalopathy (HE), hepatorenal syndrome, SBP (spontaneous bacterial peritonitis), and esophageal varices. KATA KUNCI: CEA, cost-effectiveness analysis, ChildTurcotte-Pugh Score, sirosis hepatik, hematemesis-melena, vitamin K, transamin alcoholic cirrhosis will develop esophageal varices after 2 years after being diagnosed, and 70-80% patients in 10 years. About 25-35% patients with cirrhosis and large esophageal varices will experience variceal haemorrhage. Acute variceal haemorrhage is a complication of cirrhosis which has life threatening impact (2) , and acts as a major cause of death in cirrhosis patients (8) . The increase in portal pressure due to increased resistance to blood flow to the liver is largely due to the distortion of the liver structure to fibrous tissue and regenerative nodules and intra hepatic active vasoconstriction by 20% -30% of the increased intra hepatic resistance, and a decrease in endogenous production of nitric oxide. (9) One of the functions of the liver is to produce several clotting factors (including prothrombin and fibrinogen) as well as to produce bile salts that are necessary for gastrointestinal absorption of vitamin K, which is needed to produce coagulation factor. (10) Methods various regimens used for prophylaxis and treatment of cirrhosis-related complications, and found it necessary to evaluate the costs and complications of cirrhosis-related complications. (13) Cost-effectiveness analysis (CEA) used in accordance to the study objectives in assessing relationship between cost and outcome, which in this case is clinical outcome, and CEA is an important instrument in setting priorities for strategic planning of therapy. By measuring and comparing cost and consequences of an intervention, efficient relationship could be assessed and the resources needed in the future could be estimated. (14) This study was a non-experimental research and used the retrospective approach. Data were obtained from adult patients' medical records which had major diagnosed hepatic cirrhosis cases.
In this study, the method used was CEA. Therapeutic cost and consequences of therapy were measured and compared.
Research variables
Dependent variables in this study were cost (cost of vitamin K and combination of vitamin K-transamin) and clinical outcome (duration of cessation of bleeding). Independent variables in this study were type of treatment and CTP score. Calculation of sample's number in this study: N = p.q. (Z 1/2a /b) 2 = 0.5 x 0.5 x (1.96/0.2) 2 = 24 patients Thus, the number of samples needed in each intervention group was 6 patients.
Population and sample

Inclusion and Exclusion Criteria
Inclusion criteria in this study were hepatic cirrhosis patients with hematemesis-melena, adult age ≥ 16 years (16) , and patients treated with vitamin K or combination of vitamin K-transamin. Exclusion criteria were patients who went home before the bleeding stopped, had not improved their clinical outcome, or died; patients who had not recovered from bleeding; patients with another kind of disease like hepatoma, or used another medication (for example oral vitamin K or oral transamin), which could interfere the treatment studied and outcome relationship; incomplete patient's medical record including diagnoses or clinical outcomes.
Data Analysis Techniques
Data obtained were analyzed with statistical method. First the normality of data was examined, then parametric (Anova one way, independent t-Test, and pooled t-Test) or non-parametric tests (Kruskal Wallis and Mann Whitney U test) were used to know the difference in duration of treatment until the bleeding stopped and the costs. Degree of significance used for the tests was 0.05 and the statistical program used was SPSS 17.0. Besides, conclusions were also made using cost-effectiveness grid and average costeffectiveness ratio (ACER) calculation.
Calculation of ACER
ACER was calculated based on the following formula(5) : ACER = cost / effectiveness.
Results
Effectiveness was calculated based on the percentage of cumulative duration of treatment until improvement was less than or equal to 1 day in all patients and in patients with CTP Score A and B, as well as the duration of treatment to improve less than or equal to 3 days in patients with CTP Score C. CTP Based on the effectiveness of therapy, in patients with CTP Score A found that vitamin K was more effective than vitamin K-effectiveness transamin although the difference was rather slight, in all patients and patients with CTP Score B and C, the effectiveness of vitamin K-transamin was greater than vitamin K. While the cost of treatment was only calculated based on the average cost of the therapeutic use of vitamin K and vitamin K-transamin based on the length of treatment to get better. The higher the severity of liver cirrhosis, the longer the treatment will take and therefore contributes to the increasing number of drugs used to stop bleeding and will ultimately affect the cost of the used drugs. Based on calculation with ACER, it showed that vitamin K was more cost-effective than vitamin K-transamin in all patients as well as patients with CTP Score A, B, and C.
At the test time difference of improving the treatment of the samples using parametric and nonparametric methods of analysis showed a significant difference (α=0.05) in comparison to the longer treatment improved in patients with CTP Score A, B and C (Table 4) . Comparison of the lengths of time of treatment to improve in patients with vitamin K therapy in patients with CTP Score A and B were not significant, while comparison of the CTP Score A and C with B and C showed significant differences. The duration lengths of treatment to improve therapy in patients with vitamin K-transamin in patients with CTP Score A and B were not significant, while in comparison the CTP Score A and C with B and C it showed significant differences (α=0.05). The result of the CTP Score, duration of treatment to improve the comparison between patients using vitamin K and vitamin K-transamin was not significant at the CTP Score A and B, while the CTP Score C results were significant (α=0.05). Based on the cost of the use of vitamin K only and vitamin K-transamin in the study samples, the result was a significant difference in comparison with the cost of treatment using vitamin K and vitamin K-transamin liver cirrhosis in patients with CTP Score A, B, and C (Table  6) . Table 6 . ACER in patients with CTP Score A, B and C.
in deterioration in the portal venous outflow, vascular micro thrombosis secondary to vascular ischemia and infarction may lead to the heart, with the loss of liver tissue (parenchymal extinction) being replaced by fibrotic tissue. (20) The incident is most commonly caused by portal PVT that can contribute to significant morbidity and mortality. Cirrhotic patients with PVT should be screened for varices and then anti coagulated with low-molecular-weight heparin for at least a 6-month period. Newer evidence suggests that prophylactic anticoagulation in patients with cirrhosis may have a role in clinical management with decreased incidence of PVT and improved survival. (21) The patients characteristics can be seen in Table 3 , while patients characteristics based on CTP classification can be seen in Table 4 . p value indicates significant difference if p ≤ 0.05. In this study, there was one group with a number of samples less than 6, and it was CTP score B group using vitamin K with just 5 subjects. This was due to the limitation of hepatic cirrhosis patients with hematemesis-melena.
Discussion
One of the important pharmacist's responsibilities in clinical pharmacy is to ensure good therapeutic outcome and pharmaceutical care which must not only be safe and effective, but also have a high value from economic and humanistic aspects. In fact, pharmacy profession would not succeed in their role to provide pharmaceutical care without pharmaco-economic knowledge.(17) Therefore, pharmacoeconomic evaluation like CEA which compares cost and effectiveness of therapy is needed. (18, 19) The cost of transamin is higher than the cost of vitamin K, and to know whether addition of transamin in vitamin K monotherapy is needed in clinical practice, cost-effectiveness evaluation is required.
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The difference of liver severity will take effect on therapeutic effectiveness. The higher the liver damage, the lower the therapeutic effectiveness, due to decrease of liver function for coagulation factor synthesis (1, 22) , and if there is any hepatocellular disease or if the liver cell couldn't synthesize blood coagulation factor, vitamin K given to patients wouldn't be effective (23) .
Beside CTP Score, there is another instrument used to classify the severity of the liver damage, which is a newer method called model of end stage liver disease (MELD). There are some benefits of MELD, like no subjective assessment like CTP score (ascites, hepatic encephalopathy), but hepatologists generally do not use MELD because not all laboratories use internationalized ratio (INR) which is one of MELD components as coagulation marker in hepatic cirrhosis patient, and there is no clear value limitation on MELD. Besides that, MELD scoring needs calculation, therefore quick and simple measurement couldn't be applied. (24) In Indonesia, the biggest risk factor as the cause of hepatic cirrhosis progression of hepatitis C and B infections followed by hemochromatosis(25) rather than alcohol, because of the difference between the amount of alcohol consumed by people in western countries than people in Indonesia. The development of hepatitis C to hepatic cirrhosis usually take years or decades, with average of 20 years.(26) Most of hepatic cirrhosis patients are elderly people, usually in the range of 52-69 years old due to hepatic cirrhosis development which takes years or decades. From this study it is known that hepatic cirrhosis symptoms appears averagely at the age of 51 years and culminates at the range of 52-69 years.
In this study bleeding mostly stopped at the first day after medication, although the patient had bled for days before hospitalized. This is in accordance with literature that claims when vitamin K is given parenterally, prothrombin time (PT) may need 12 to 24 hours to normal, although improvement may happen in 1 to 2 hours (27) , whereas transamin has t 1/2 = 2 hours(28). Therefore, it is most likely that patient's bleeding could be stopped at the first day of treatment.
Anti-fibrinolytic therapy has been shown to be useful in controlling bleeding in some conditions, especially in patients with gastric erosion and also in esophageal varices. Anti-fibrinolytic effect is not associated with improved systemic fibrinolysis, but more due to the inhibition of local fibrinolysis in gastroduodenal mucosa.(10) Therefore, the use of transamin in addition to the use of vitamin K can be an option, but there is no sufficient evidence supporting a recommendation on the use of transamin in the treatment
Conclusion
The use of vitamin K therapy is more cost-effective than combination therapy of vitamin K-transamin in all patients with liver cirrhosis and hematemesis-melena, and in of gastrointestinal bleeding and bleeding from varices. (7) Regardless of the fact there is an evidence that transamin is a useful treatment for refractory bleeding due to gastric antral vascular ectasia in patients with cirrhosis. (29) Comparative effectiveness based on pharmacoeconomics reviews, performed by calculating the percentage of patients with cirrhosis of the liver with hematemesis melena ≤ 1 day in all patients and in patients with CTP Score A and B, as well as old treatment until the bleeding that stopped ≤ 3 days in patients with CTP Score C.
Data were analyzed using cost-effectiveness grid and ACER. From the cost-effectiveness in the table grid (Table  2 ) it can be seen that vitamin K has a dominant outcome in patients with CTP Score A and trade off on all patients as well as patients with CTP Score B and C. Consider further follow up on the results of the trade off is using ACER. From the dominant finding in the results, it can be seen that treatment with vitamin K have a lower cost with higher effectiveness than vitamin K-transamin, so it can be concluded that vitamin K is more cost-effective than vitamin K-transamin.
Based on the calculation of ACER (Table 5 and 6) , it showed the value of vitamin K was smaller than the vitamin K-transamin, so it can be concluded that vitamin K is more cost-effective than vitamin K-transamin in all patients as well as in patients with CTP Score A, B, and C.
There are some limitations of this study including that of the number of samples which was too small, because it was taken from 1 hospital even in 2 years, and that's why the data were not homogenous and the distribution was not normal either. We recommend that in the future studies using more samples with a longer time span should be carried out so the samples can be homogeneous and have normal distribution. The next limitation was the observed cost, in which this study only examined the cost of drugs, while other costs such as hospital and physician costs, laboratory costs, etc., were not observed. Another limitation was that the outcome of treatment was observed only until the bleeding stopped (the duration), other outcomes associated with bleeding such as PT was not observed. PT is a laboratory test needed to evaluate blood coagulation rate. Decrease of PT is an expected result from bleeding medication.
patients with CTP score A, B, and C. This conclusion should be regarded with caution due to its limitation and further research is needed.
Suggestion is given for further research using a prospective design so that the results obtained can be representative of the actual condition of the patient and confounding variables can be better controlled so as to obtain a good study of the relationship between risk factors and effects. In addition, the number of samples should be enlarged in order to get more homogeneous data and normal distribution, other components of cost such as cost of hospital, doctor, etc. could be calculated, not only the cost of therapy vitamin K or vitamin K-transamin, and the outcome observed is not only of the duration of bleeding, but also Prothrombin Time, side effects, and other factors that affect bleeding in patients.
